Affymax, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for the treatment of rare and underserved diseases. The company leverages its proprietary TransCon® drug delivery platform to create prodrugs that offer sustained, predictable release of active pharmaceutical ingredients. Affymax’s research efforts concentrate on endocrinology and nephrology indications, seeking to address conditions that currently have limited treatment options.
Among its lead product candidates, Affymax is advancing TransCon® PTH for the treatment of hypoparathyroidism and TransCon® Growth Hormone (TransCon® GH) for pediatric growth hormone deficiency. The TransCon® technology is designed to extend the half-life of therapeutic molecules, potentially improving patient adherence and reducing dosing frequency. In addition to these programs, the company is exploring applications of its platform across a broader pipeline of long-acting prodrugs.
Founded in 2002 and headquartered in Palo Alto, California, Affymax has established strategic collaborations and licensing agreements to support development and potential commercialization. The company previously brought a novel anemia treatment, OMONTYS® (peginesatide), to market in partnership with a major pharmaceutical firm, gaining valuable commercial experience despite the product’s eventual market withdrawal.
Affymax is led by President and Chief Executive Officer Glenn Mattes, whose experience in specialty pharmaceutical development and commercial operations guides the company’s strategic direction. With a dedicated team of research scientists and regulatory experts, Affymax aims to translate its scientific insights into safe, effective treatments for patients with significant unmet medical needs.
AI Generated. May Contain Errors.
